leadf
logo-loader
viewBraveheart Investment Group

Braveheart highlights progress of investee Paraytec’s development of coronavirus test

The investment group said Paraytec has completed development of a signal generation module for the test, while work has also started on a detection system

Braveheart Investment Group - Braveheart highlights progress of investee Paraytec’s development of coronavirus test

Braveheart Investment Group PLC (LON:BRH) has highlighted progress in the development of a coronavirus test by its investee company Paraytec and the University of Sheffield.

The investment group said having previously completed work packages relating to the construction of a viral mimic and the capture SYSTEM for the test, Paraytec’s development of a signal generation module, which contains a synthetic coronavirus binding protein molecule bonded to fluorescent nanospheres, has now been completed.

READ: Braveheart to sell its stake in Pharm 2 Farm to Remote Monitored Systems

Meanwhile, Braveheart said work has been initiated and continues to progress on building an optical detection system, which is used to detect and quantify the fluorescent nanospheres that bind the CAPTURE Module in the presence of the virus.

In order to evaluate the operating characteristics of the system, Paraytec has built CAPTURE microspheres coated with fluorescent SIGNAL GENERATION components for the purposes of visualisation and quantitation, with detection of the fluorescent microspheres achieved using a very high sensitivity photodiode that responds to single photons of light, generating an "avalanche" of electrons and registering the presence of viral particles.

In a statement, Professor Carl Smythe from Sheffield University said: "We are pleased with Paraytec's continued progress in building this rapid test.  A key issue associated with [coronavirus] testing will be the detection of disease in people who have very low levels of viral particles in swab or saliva samples. By using a highly sensitive detection system, the test will maximise the potential to detect asymptomatic carriers of the virus.  Over the next month, we will be undertaking proof-of-concept testing, which we hope to complete by early October."

Quick facts: Braveheart Investment Group

Price: 54.5 GBX

AIM:BRH
Market: AIM
Market Cap: £19.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Braveheart Investment Group named herein, including the promotion by the Company of Braveheart Investment Group in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Braveheart Investment Group Pharm2Farm designs antiviral face mask to kill...

Braveheart Investment Group PLC (LON:BRH) investee company Pharm2Farm's (P2F) Gareth Cave talks to Proactive London about their new antiviral face mask that can kill coronavirus (COVID-19). Cave talks through the technology behind the mask, which is says is much stronger than the standard...

on 26/10/20

2 min read